Trials / Withdrawn
WithdrawnNCT04853524
A Study of JNJ-56136379 in Healthy Participants
A Phase 1, Open-label Study in Healthy Participants to Investigate the Effect of Multiple-dose JNJ-56136379 on the Single-dose Pharmacokinetics of Bictegravir, Emtricitabine, and Tenofovir Alafenamide
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of multiple-dose JNJ-56136379 on the single-dose pharmacokinetics (PK) of the combination of bictegravir (BIC), emtricitabine (FTC), tenofovir alafenamide (TAF) in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-56136379 | JNJ-56136379 tablets will be administered orally. |
| DRUG | Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) | A combination of BIC, FTC and TAF will be administered orally. |
Timeline
- Start date
- 2021-05-06
- Primary completion
- 2021-06-15
- Completion
- 2021-07-30
- First posted
- 2021-04-21
- Last updated
- 2021-07-15
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04853524. Inclusion in this directory is not an endorsement.